Trial watch: Dendritic cell-based interventions for cancer therapy
Dendritic cells (DCs) occupy a central position in the immune system, orchestrating a wide
repertoire of responses that span from the development of self-tolerance to the elicitation of …
repertoire of responses that span from the development of self-tolerance to the elicitation of …
Preservation of cell-based immunotherapies for clinical trials
In the unique supply chain of cellular therapies, preservation is important to keep the cell
product viable. Many factors in cryopreservation affect the outcome of a cell therapy:(i) …
product viable. Many factors in cryopreservation affect the outcome of a cell therapy:(i) …
Next‐generation peptide vaccines for advanced cancer
A Yamada, T Sasada, M Noguchi, K Itoh - Cancer science, 2013 - Wiley Online Library
Many clinical trials of peptide vaccines have been carried out since the first clinical trial of a
melanoma antigen gene‐1‐derived peptide‐based vaccine was reported in 1995. The …
melanoma antigen gene‐1‐derived peptide‐based vaccine was reported in 1995. The …
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence …
OE Rahma, E Ashtar, M Czystowska… - Cancer Immunology …, 2012 - Springer
Purpose Peptide antigens have been administered by different approaches as cancer
vaccine therapy, including direct injection or pulsed onto dendritic cells; however, the …
vaccine therapy, including direct injection or pulsed onto dendritic cells; however, the …
[HTML][HTML] Promising new tools for targeting p53 mutant cancers: Humoral and cell-based immunotherapies
V Chasov, M Zaripov, R Mirgayazova… - Frontiers in …, 2021 - frontiersin.org
Transcription factor and oncosuppressor protein p53 is considered as one of the most
promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene …
promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene …
[HTML][HTML] mRNA vaccination in breast cancer: current progress and future direction
X Jiang, Q Liu - Journal of Cancer Research and Clinical Oncology, 2023 - Springer
Messenger RNA (mRNA) vaccination has proven to be highly successful in combating
Coronavirus disease 2019 (COVID-19) and has recently sparked tremendous interest. This …
Coronavirus disease 2019 (COVID-19) and has recently sparked tremendous interest. This …
[HTML][HTML] Clinical and immunological effects of p53-targeting vaccines
Immunotherapy, including immune checkpoint blockade and chimeric antigen receptor T
cells, is one of the most promising approaches to treat cancer. Vaccines have been effective …
cells, is one of the most promising approaches to treat cancer. Vaccines have been effective …
Immunotherapy in breast cancer
S Bayraktar - Breast Disease: Management and Therapies, Volume …, 2019 - Springer
Immunotherapy for the treatment of breast cancer can be categorized as either (a) specific
stimulation of the immune system by active immunization with cancer vaccines or (b) passive …
stimulation of the immune system by active immunization with cancer vaccines or (b) passive …
Breast cancer vaccination: Latest advances with an analytical focus on clinical trials
MK Vajari, MJ Sanaei, S Salari, A Rezvani… - International …, 2023 - Elsevier
Breast cancer (BC) is one of the main causes of cancer-related death worldwide. The
heterogenicity of breast tumors and the presence of tumor resistance, metastasis, and …
heterogenicity of breast tumors and the presence of tumor resistance, metastasis, and …
[图书][B] Animal lectins: form, function and clinical applications
GS Gupta - 2012 - books.google.com
Animal Lectins: Form, Function and Clinical Applications presents up-to-date knowledge of
animal lectins. Detailed descriptions on biological activities, tissue and/or subcellular …
animal lectins. Detailed descriptions on biological activities, tissue and/or subcellular …